<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="COVID-19 is feverishly being investigated to identify the best available" exact="treatment" post="options for dealing with the current wave of disease."/>
 <result pre="therapeutics are showing promise: those with antiviral activity directly addressing" exact="infection" post="and those that counteract the inflammatory cytokine storm induced"/>
 <result pre="therapies for coronavirus disease 2019 have antiviral activity for addressing" exact="infection" post="directly or counteract the inflammatory cytokine storm induced by"/>
 <result pre="for clinical benefit must be balanced with the expediency of" exact="treatment" post="need. Numerous therapies with a wide variety of mechanisms"/>
 <result pre="and provide a succinct summary of the science supporting each" exact="treatment" post="strategy and the pipeline of clinical trials. Methods To"/>
 <result pre="Middle East respiratory syndrome (MERS), and Ebola have emerged as" exact="treatment" post="options because of their known safety profiles and availability."/>
 <result pre="from inhibition of viral replication and RNA synthesis.8,9 Data supporting" exact="treatment" post="of SARS-CoV-2 infection with remdesivir include established potency against"/>
 <result pre="viral replication and RNA synthesis.8,9 Data supporting treatment of SARS-CoV-2" exact="infection" post="with remdesivir include established potency against coronaviruses inÂ vitro8"/>
 <result pre="half-maximal effective concentration (EC50) of 0.77 Î¼M and inhibition of" exact="infection" post="in Huh-7 cells.12 Combination with emetine may enhance viral"/>
 <result pre="and the United States have provided early promising results of" exact="treatment" post="with remdesivir, usually in combination with other agents.14, 15,"/>
 <result pre="placebo (P&amp;lt;.001).21 However, a randomized, multicountry, open-label trial of remdesivir" exact="treatment" post="for 5 or 10 days in 397 patients with"/>
 <result pre="mechanical ventilation determined no difference in 14-day clinical improvement between" exact="treatment" post="groups on an ordinal scale (64% of patients improving"/>
 <result pre="immunodeficiency virus type 1 protease and are used in the" exact="treatment" post="of human immunodeficiency virus infection and AIDS. Reports of"/>
 <result pre="and are used in the treatment of human immunodeficiency virus" exact="infection" post="and AIDS. Reports of the potentially successful use of"/>
 <result pre="Reports of the potentially successful use of LPV/RTV in the" exact="treatment" post="of MERS27,28 and an ongoing clinical trial29 have led"/>
 <result pre="time was correlated with hospital length of stay in LPV/RTV" exact="treatment" post="groups (P=.0215 and P=.012),33 and patients receiving LPV/RTV, arbidol,"/>
 <result pre="therapy revealed no improvement in symptoms or viral clearance from" exact="treatment" post="(P&amp;gt;.05).36,37 A 199-patient RCT of LPV/RTV in patients with"/>
 <result pre="(ICU) length of stay.38 The results of an RCT comparing" exact="treatment" post="with LPV/RTV and arbidol in 86 patients with mild/moderate"/>
 <result pre="as tocilizumab and sarilumab are of great interest for the" exact="treatment" post="of COVID-19. Janus kinase (JAK) inhibitors such as baricitinib"/>
 <result pre="to 6.7; P&amp;lt;.05).59 Conversely, a 21-patient retrospective analysis of tocilizumab" exact="treatment" post="in Italy did not find reductions in ICU admission"/>
 <result pre="5-fold higher than those in patients with normoglycemia and that" exact="treatment" post="failed to attenuate the risk of severe outcomes in"/>
 <result pre="reported a 58% decline in inflammation scores 7 days after" exact="treatment" post="with ruxolitinib (P&amp;lt;.01) and 76% of patients had clinical"/>
 <result pre="are quinine analogues that have been widely used in the" exact="treatment" post="of malaria and autoimmune diseases such as rheumatoid arthritis"/>
 <result pre="viral clearance, body temperature, or radiological progression compared to conventional" exact="treatment" post="(P&amp;gt;.05).79 An article describing a 150-patient open-label RCT also"/>
 <result pre="mortality, ICU admission, or ventilation rates was observed with HCQ" exact="treatment" post="in retrospective analyses of 368 US patients (P&amp;gt;.05)81 and"/>
 <result pre="and mortality.84 The first double-blind, RCT of postexposure prophylactic HCQ" exact="treatment" post="found no apparent decrease in incidence between treatment and"/>
 <result pre="prophylactic HCQ treatment found no apparent decrease in incidence between" exact="treatment" post="and placebo groups (11.8% vs 14.3%; P=.35) in 821"/>
 <result pre="In an open-label nonrandomized trial in 36 French patients, HCQ" exact="treatment" post="virologically cured 57% of patients (100% of patients when"/>
 <result pre="when used in conjunction with azithromycin) within 6 days of" exact="treatment" post="compared with 12.5% of control patients (P&amp;lt;.001).86 Although a"/>
 <result pre="combination therapy found that only 20% of patients using this" exact="treatment" post="tested negative for SARS-CoV-2 at days 5 to 6"/>
 <result pre="CQ or HCQ treatment.94 Of note, one large study suggesting" exact="treatment" post="with CQ or HCQ increases risk of in-hospital mortality"/>
 <result pre="clinical improvement on a 6-point scale within 28 days of" exact="treatment" post="for 51.9% of patients receiving CPT compared with 43.1%"/>
 <result pre="viral clearance was achieved in 87.2% of patients in the" exact="treatment" post="group compared with 37.5% in the control group (P&amp;lt;.001);"/>
 <result pre="biologic, and RNA-based therapies are being actively developed for the" exact="treatment" post="of COVID-19 (reviewed in reference 115) and will be"/>
 <result pre="WHO-sponsored, adaptive RCT open to any patient with confirmed SARS-CoV-2" exact="infection" post="worldwide. On the basis of institutional drug availability, patients"/>
 <result pre="capture, and an adaptive design to allow the modification of" exact="treatment" post="arms on the basis of evolving evidence. An example"/>
 <result pre="vitro studies, remdesivir is a leading antiviral candidate for the" exact="treatment" post="of COVID-19. The results of CQ and HCQ clinical"/>
 <result pre="therapies and increasingly suggest limited, if any, benefit for the" exact="treatment" post="of COVID-19. Similarly, reports of the use of convalescent"/>
 <result pre="and efficacy of glucocorticoids and other immunosuppressive drugs for the" exact="treatment" post="of SARS-CoV-2â€&quot;associated cytokine storm, including timing, dose, and duration"/>
 <result pre="know whether observed clinical improvements are the result of the" exact="treatment" post="or may have occurred anyway. These studies do, however,"/>
 <result pre="allow ethical enrollment in the RCTs that will definitively measure" exact="treatment" post="safety and efficacy. Clinicians, scientists, patients, and their families"/>
 <result pre="beta against MERS-CoVNature Commun111202022231924756 11de WitE.FeldmannF.CroninJ.Prophylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infectionProc Natl"/>
 <result pre="disease 2019 (COVID-19) in the United StatesNat Med266202086186832327757 18AntinoriS.CossuM.V.RidolfoA.L.Compassionate remdesivir" exact="treatment" post="of severe Covid-19 pneumonia in intensive care unit (ICU)"/>
 <result pre="placebo-controlled, multicentre trialLancet3951023620201569157832423584 21BeigelJ.H.TomashekK.M.DoddL.E.collab: ACTT-1 Study Group MembersRemdesivir for the" exact="treatment" post="of Covid-19â€&quot;preliminary report [published online ahead of print May"/>
 <result pre="of action of T-705 against influenza virusAntimicrob Agents Chemother493200598198615728892 25CaiQ.YangM.LiuD.Experimental" exact="treatment" post="with favipiravir for COVID-19: an open-label control study [published"/>
 <result pre="serological analysis of a recent Middle East respiratory syndrome coronavirus" exact="infection" post="case on a triple combination antiviral regimenInt J Antimicrob"/>
 <result pre="infected discharged patientsInflamm Res696202059960632227274 34YeX.T.LuoY.L.XiaS.C.Clinical efficacy of lopinavir/ritonavir in the" exact="treatment" post="of coronavirus disease 2019Eur Rev Med Pharmacol Sci24620203390339632271456 35HungI.F.N.LungK.C.TsoE.Y.K.Triple"/>
 <result pre="35HungI.F.N.LungK.C.TsoE.Y.K.Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the" exact="treatment" post="of patients admitted to hospital with COVID-19: an open-label,"/>
 <result pre="phase 2 trialLancet3951023820201695170432401715 36ChenJ.LingY.XiX.H.Efficacies of lopinavir/ritonavir and abidol in the" exact="treatment" post="of novel coronavirus pneumoniaChin J Infect Dis382020E008 37ZhuZ.LuZ.XuT.Arbidol monotherapy"/>
 <result pre="online ahead of print March 16, 2020]medRxivhttps://doi.org/10.1101/2020.03.12.20034736 49RichardsonP.GriffinI.TuckerC.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseLancet395102232020e30e3132032529 50StebbingJ.PhelanA.GriffinI.COVID-19: combining antiviral and"/>
 <result pre="glucosteroids: the Guangzhou experienceChest129620061441145216778260 53SungJ.J.Y.WuA.JoyntG.M.Severe acute respiratory syndrome: report of" exact="treatment" post="and outcome after a major outbreakThorax595200441442015115870 54XuX.HanM.LiT.Effective treatment of"/>
 <result pre="report of treatment and outcome after a major outbreakThorax595200441442015115870 54XuX.HanM.LiT.Effective" exact="treatment" post="of severe COVID-19 patients with tocilizumabProc Natl Acad Sci"/>
 <result pre="patients with tocilizumabProc Natl Acad Sci U S A117202020109701097532350134 55LuoP.LiuY.QiuL.LiuX.LiuD.LiJ.Tocilizumab" exact="treatment" post="in COVID-19: a single center experienceJÂ Med Virol927202081481832253759 56KlopfensteinT.ZayetS.LohseA.collab:"/>
 <result pre="with COVID-19 related pneumoniaEur J Intern Med762020313532405160 58ToniatiP.PivaS.CattaliniM.Tocilizumab for the" exact="treatment" post="of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute"/>
 <result pre="60ColaneriM.BoglioloL.ValsecchiP.collab: The Covid Irccs San Matteo Pavia Task ForceTocilizumab for" exact="treatment" post="of severe COVID-19 patients: preliminary results from SMAtteo COvid19"/>
 <result pre="BonoS.collab: Sacco Baricitinib Study GroupMechanism of baricitinib supports artificial intelligence-predicted" exact="testing" post="in COVID-19 patientsEMBO Mol Med1282020e1269732473600 63CantiniF.NiccoliL.MatarreseD.NicastriE.StobbioneP.GolettiD.Baricitinib therapy in COVID-19:"/>
 <result pre="online ahead of print June 24, 2020]J Infecthttps://doi.org/10.1016/j.jinf.2020.06.052 65CaoY.WeiJ.ZouL.Ruxolitinib in" exact="treatment" post="of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind,"/>
 <result pre="Infect Dis119201167768321550310 75TricouV.MinhN.N.VanT.P.AÂ randomized controlled trial of chloroquine for the" exact="treatment" post="of dengue in Vietnamese adults [published correction appears in"/>
 <result pre="Trop Dis. 2012;6(6)]PLoS Negl Trop Dis482010e78520706626 76De LamballerieX.BoissonV.ReynierJ.C.On chikungunya acute" exact="infection" post="and chloroquine treatmentVector Borne jDis862008837840 77LiuJ.CaoR.XuM.Hydroxychloroquine, a less toxic"/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="inÂ vitroCell Discov620201632194981 78YaoX.YeF.ZhangM.InÂ vitro antiviral activity and projection"/>
 <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect"/>
 <result pre="2 (SARS-CoV-2)Clin Infect Dis7115202073273932150618 79ChenJ.LiuD.LiuL.AÂ pilot study of hydroxychloroquine in" exact="treatment" post="of patients with common coronavirus disease-19 (COVID-19)JÂ Zhejiang Univ"/>
 <result pre="in hospitalized patients with Covid-19NÂ Engl J Med3822520202411241832379955 84RosenbergE.S.DufortE.M.UdoT.Association of" exact="treatment" post="with hydroxychloroquine or azithromycin with in-hospital mortality in patients"/>
 <result pre="for Covid-19NÂ Engl J Med3836202051752532492293 86GautretP.LagierJ.-C.ParolaP.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt"/>
 <result pre="Infect Dis34202010166332289548 88DahleyD.GatesS.OrrisT.Statistical review of hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial"/>
 <result pre="2020]ResearchGatehttps://doi.org/10.13140/RG.2.2.24669.36325 90Statement on IJAA paper: Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial"/>
 <result pre="azithromycin in patients with severe COVID-19 infectionMed Mal Infect504202038432240719 92MillionM.LagierJ.-C.GautretP.Early" exact="treatment" post="of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective"/>
 <result pre="95MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for" exact="treatment" post="of COVID-19: a multinational registry analysis [published online ahead"/>
 <result pre="under hydroxychloroquine/azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract" exact="infection" post="[published online ahead of print June 26, 2020]Clin Pharmacol"/>
 <result pre="as a potential therapy for COVID-19Lancet Infect Dis204202039840032113510 102KeithP.DayM.PerkinsL.MoyerL.HewittK.WellsA.AÂ novel" exact="treatment" post="approach to the novel coronavirus: an argument for the"/>
</results>
